

Curriculum Vitae

1. **Name:** Waraporn Saentaweasuk
2. **Work address:** Faculty of Pharmacy, Mahasarakham University
3. **Education:**
 1. B. Pharm. Pharmaceutical Sciences 2009
Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand
 2. Ph. D. Medical Biochemistry and Molecular Biology 2018
Faculty of Medicine, Khon Kaen University, Thailand
4. **Research training (during Ph. D. course):** Research in proteomic analysis and cancer biology under supervision of Assoc. Prof. Dr. Norie Araki, Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
5. **Publications:**
 1. Thammavong S, Phadungkit M, Laovachirasuwan P, Naksuwankul K, Saentaweasuk W, Silsirivanit A, Wongkham S. Antioxidant and cytotoxic activity of Phellinus mushrooms from northeast Thailand. Research Journal of Pharmacognosy. 2021 Jan;8(1):91-99.
 2. Luang S, Teeravirote K, Saentaweasuk W, Ma-In P, Silsirivanit A. Carbohydrate Antigen 50: Values for Diagnosis and Prognostic Prediction of Intrahepatic Cholangiocarcinoma. Medicina (Kaunas). 2020 Nov 16;56(11):616.
 3. Wattanavises S, Silsirivanit A, Sawanyawisuth K, Cha'on U, Waraasawapati S, Saentaweasuk W, Luang S, Chalermwat C, Wongkham C, Wongkham S. Increase of MAL-II Binding Alpha2, 3-Sialylated Glycan Is Associated with 5-FU Resistance and Short Survival of Cholangiocarcinoma Patients. Medicina. 2019 Nov;55(12):761.
 4. Chalermwat C, Silsirivanit A, Saentaweasuk W, Bhudisawasdi V, Pairojkul C, Khahmahpahte S, Thanong T, Changtrakul Y, Pintaraks K, Wongkham C, Wongkham S. Neutrophil-to-Lymphocyte Ratio: A Systemic Inflammatory Index for Primary Diagnosis and Prognosis of Cholangiocarcinoma. Biomedical Journal of Scientific & Technical Research. 2019;13(2):9857-64.
 5. Saentaweasuk W, Araki N, Vaeteewoottacharn K, Silsirivanit A, Seubwai W, Talabnin C, Muisuk K, Sripa B, Wongkham S, Okada S, Wongkham C. Activation of vimentin is critical to promote a metastatic potential of cholangiocarcinoma cells. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 2018 May 7;26(4):605-16.
 6. Saentaweasuk W, Silsirivanit A, Vaeteewoottacharn K, Sawanyawisuth K, Pairojkul C, Cha'on U, Indramanee S, Pinlaor S, Boonmars T, Araki N, Wongkham C. Clinical significance of GalNAcylated glycans in cholangiocarcinoma: Values for diagnosis and prognosis. Clinica Chimica Acta. 2018 Feb 1;477:66-71.
6. **Specialty and interest**
 - Molecular biology and metastasis of cancer
 - Proteomic analysis
 - Pharmacological activities of herbal extracts/synthetic compounds